McKesson accused of skimming profit, harming patients

Apr

05

McKesson accused of skimming profit, harming patients

The federal government and 31 states have sued the wholesale drug distributor McKesson Corp. for allegedly repackaging leftover cancer drugs from single-use vials at the expense of the government and patients.

McKesson is one of the largest pharmaceutical distributors in the country and is accused of violating the False Claims Act. The lawsuit, filed late Tuesday in the U.S. District Court for the Eastern District of New York, alleges it sold the “overfill” from vials of Aloxi, Procrit and other oncology drugs from 2001 to at least 2010 to cancer centers, medical practices and physicians. The providers would then bill the government for the drugs.

The government alleged McKesson intentionally put cancer patients at serious risk for infection while defrauding federal, state and local governments out of hundreds of millions of dollars.

McKesson “learned that they could maximize profits at the governments’ expense by harvesting overfill in covered drug products such as the oncology drugs, pooling the oncology drugs, and then repackaging them in bulk into non-sterile and plastic pre-filled syringes, despite the clear risk to vulnerable cancer patients,” the complaint said.

The vials are labeled single-use because the drugs don’t have preservatives that prevent bacterial growth. Also, distributors aren’t charged for overfill, and the providers they sell the drugs to are not allowed to bill the government for it because they were repackaged in unapproved facilities. That allegedly allowed McKesson to offer discounts to providers for the pre-filled syringes, which they would purchase instead of the vials, amounting to a kickback, according to the complaint.

The plaintiffs include the federal government, 31 states, the cities of Chicago and New York, and Omni Healthcare, which received cancer drugs from McKesson.

McKesson could face a $10,000 fine per False Claims Act violation, plus three times the amount of the damages sustained by the government. McKesson’s competitor AmerisourceBergen was accused of similar behavior in another case that resulted in fines, penalties and a civil settlement that amounted to nearly $1 billion, according to court records.

McKesson said it is currently reviewing the complaint.

If the allegations hold up, the penalties have to hurt McKesson’s financial condition enough to change its behavior, said Kerry Harvey, a member at the law firm Dickinson Wright.

“It gets down to a simple cost-benefit analysis,” he said. “Does the potential risk of penalties outweigh the very real benefit of taking these liberties with the rules? Or else it runs the risk of being written off.”

The case carries more weight given the allegations of patient safety impacts, added Harvey, a former U.S. attorney for the Eastern District of Kentucky.

In addition to allegedly “fraudulently inducing reimbursements,” the overfill inflated the average sales price of the drugs that the government overpaid for, according to the lawsuit.

McKesson is part of the “big three” wholesale drug distributors, along with AmerisourceBergen and Cardinal Health, which collectively have more than 85% market share of the pharmaceutical supply chain. McKesson supplies more than 40,000 healthcare facilities in the U.S. The company reported nearly $200 billion in revenue in 2017, the vast majority of which comes from its distribution solutions business.

The government claimed that the company’s alleged “profit motive” also caused them to contaminate the previously sterile drugs by skimming overfill and shipping and storing the products improperly.

McKesson “presumably assumed that any infections and resulting patient deaths would likely be falsely attributed to the patients’ disease and treatment, as opposed to healthcare providers’ unwittingly administering non-sterile and unapproved drugs,” the complaint said.

Allegedly, an Omni employee saw McKesson employees pool overfill from the FDA-approved packages of the cancer drugs in a non-sterile environment and facility in Frisco, Texas. The products were then placed into pre-filled syringes that were re-labeled—in some instances with fake product codes and expiration dates, according to the lawsuit.

Also, McKesson subsidiary U.S. Oncology and its affiliated physician offices would allegedly extract a dose, collect what’s leftover from the single-use vials and then bill the government for that overfill, according to court records.

In March 2000, the drug manufacturer Amgen sent a letter to providers regarding 21 reported cases of patient reactions resulting from the contaminated drug Epogen, which treats anemia caused by chemotherapy. The letter reminded providers that “multiple entries should not be made into single-dose vials, and residual medication from two or more vials should not be pooled into a single vial. … Once a syringe has entered a single-dose vial, the sterility of the product can no longer be guaranteed.”

These types of repackaging practices came under more scrutiny following a deadly meningitis outbreak in 2012 that was traced to contaminated injections of medical steroids made by the New England Compounding Center in Framingham, Mass.

Hundreds of cities, counties and states across the country are also suing the big three drug distributors for allegedly not flagging suspicious opioid prescriptions.

“Some of the most senior government officials charged with ensuring the health and safety of Americans recently publicized their concerns that defendants are above the law—that they have harmed and will continue to harm millions of Americans, for profit, and with impunity,” the complaint said. “As evident in this action, (McKesson) continues to elect corporate revenue over patient safety.”